Helixmith Participates in US Bio CEO & Investor Conference

[Asia Economy Reporter Jang Hyowon] Helixmith announced on the 17th that it participated in the ‘BIO CEO & Investor Conference’ held over four days from the 14th in New York, USA. Helixmith CEO Kim Sun-young attended the event in person to introduce the company’s pipeline technology and the latest clinical status, and engaged in efficient and in-depth discussions with participating companies.

Now in its 24th year, the ‘BIO CEO & Investor Conference’ is an event where major global big pharma companies gather to share the latest bio issues. Over 460 multinational pharmaceutical and biotech companies, institutional investors, and researchers from around the world attended, presenting agendas by field and conducting one-on-one partnering meetings.

CEO Kim introduced Helixmith’s gene therapy platform, focusing especially on the clinical development status of Enzygnis (VM202). In addition, through one-on-one partnering meetings with interested companies, discussions were held regarding technology transfer and investment possibilities.

Helixmith’s gene therapy drug, Enzygnis (VM202), is a plasmid DNA-based gene therapy that expresses the HGF protein. It is characterized not simply by managing pain but by targeting the root causes of neuropathy through angiogenesis and nerve regeneration effects.

The U.S. FDA recognized the scientific and clinical results of Enzygnis (VM202) and designated it as a Regenerative Medicine Advanced Therapy (RMAT) in 2018. This is the first gene therapy for a widespread disease affecting millions of patients in the U.S. to receive RMAT designation. Clinical trials are currently underway targeting various diseases such as diabetic peripheral neuropathy (DPN), amyotrophic lateral sclerosis (ALS), and Charcot-Marie-Tooth disease (CMT).

CEO Kim said, “At this event, we informed global companies and investors about the excellence and clinical status of Enzygnis (VM202). We also held partnering meetings with numerous big pharma companies and hope these will lead to meaningful outcomes.”

This content was produced with the assistance of AI translation services.